Accessing Investigational Products Outside of a Trial: Considerations for Neuromuscular Providers

Author:

Bedlack R. S.ORCID,Cudkowicz M. E.,Paganoni S.,Khan-Tareen H.,Andrews J. A.

Abstract

Abstract Purpose of Review People with fatal neuromuscular diseases such as ALS want to access investigational products. Trials are our preferred pathway for this, but most people with these diseases will not be able to participate due to restrictive inclusion criteria, travel burdens, or design features they will not accept. This leaves FDA Expanded Access Programs (EAPs), the Right To Try (RTT) pathway, and self-purchase of alternative and off-label treatments (AOTs). Recent Findings A recent survey highlighted physician barriers to the above pathways, including lack of knowledge and concerns about time burdens and risks. Emerging resources are highlighted that can mitigate some of these concerns. Summary With the information in this chapter, we hope that neuromuscular clinicians will feel more knowledgeable and confident in supporting patient request for investigational products.

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical)

Reference39 articles.

1. • Bedlack RS, Pastula DM, Welsh E, Pulley D, Cudkowicz M. Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotrophic Lateral Sclerosis 2008;9:257–265. Highlights the low enrollment in ALS trials.

2. • Bedlack RS, Wicks Paul, Heywood J, Kasarskis E. Modifiable barriers to enrollment in American ALS research studies. Amyotrophic Lateral Sclerosis 2010;11:502–507. Explains some of the barriers to enrollment in ALS trials, only some of which are easily modifiable.

3. Nichols E; Institute of Medicine (US) Roundtable for the Development of Drugs and Vaccines Against AIDS. Expanding access to investigational therapies for HIV infection and AIDS: March 12–13, 1990 Conference Summary. Washington (DC): National Academies Press (US). 1991;1. Historical Perspective. Available from: https://www.ncbi.nlm.nih.gov/books/NBK234129/

4. US Food and Drug Administration webpage on Expanded Access. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312&showFR=1&subpartNode=21:5.0.1.1.3.9 (2020). Accessed 5-May-2021.

5. National Institute of Health Center for Leading Innovation & Collaboration. https://clic-ctsa.org/groups/teamss/navigating-expanded-access#section1 (2020). Accessed 6-May-2021.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3